16. クロウ・深瀬症候群 Crow-Fukase syndrome Clinical trials / Disease details
臨床試験数 : 13 / 薬物数 : 18 - (DrugBank : 8) / 標的遺伝子数 : 5 - 標的パスウェイ数 : 81
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01639898 (ClinicalTrials.gov) | July 2012 | 5/7/2012 | POEMS Syndrome Treatment With Lenalidomide | Phase II Trial With Lenalidomide-Dexamethasone Combination in the Treatment of POEMS Syndrome. | POEMS Syndrome | Drug: Lenalidomide and dexamethasone | University Hospital, Limoges | Ministry of Health, France;Celgene Corporation | Completed | 18 Years | N/A | All | 51 | Phase 2 | France |
| 2 | NCT00971685 (ClinicalTrials.gov) | July 2009 | 3/9/2009 | The Treatment of Lenalidomide in Patients With POEMS Syndrome | Evaluation of Efficacy and Safety of Lenalidomide (Revlimid®) in Patients With POEMS Syndrome | POEMS Syndrome | Drug: Lenalidomide and dexamethasone | Istituto Clinico Humanitas | NULL | Recruiting | 18 Years | N/A | Both | 16 | Phase 2 | Italy |